Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Apretude
Pharma
GSK questions Gilead's potential dominance of the PrEP market
A couple of aspects with Gilead's lenacapavir have GSK's execs thinking they can compete in the long-acting PrEP market for HIV.
Angus Liu
Feb 6, 2025 2:20pm
GSK bolsters case for long-acting HIV PrEP drug Apretude
Oct 16, 2024 1:26pm
GSK to triple long-acting Apretude supply to boost global access
Oct 7, 2024 10:56am
Gilead races toward filings for long-acting PrEP after trial win
Sep 12, 2024 11:45am
MSF calls out GSK's ViiV for nondisclosure clauses in contract
Aug 17, 2023 2:54pm
Viatris, Cipla and Aurobindo sign up to make GSK PrEP generics
Mar 30, 2023 2:00am
